Polyglutamine ataxias are autosomal dominantly inherited neurodegenerative disorders in which the molecular aetiology is an expanded CAG glutamine-encoding repeat in the causative genes. At present, there is no effective treatment, but there are several ongoing trials addressing polyglutamine disorders increasing the need of knowledge about prevalence and relative frequencies of the different subtypes. To identify all individuals with genetically confirmed polyglutamine ataxia in Denmark, determine frequency of subtypes and estimate the incidences.
View Article and Find Full Text PDFImatinib mesylate (IM) is a widely used anticancer drug, mainly for treating chronic myeloid leukemia. However, pharmaceutical formulations may contain impurities, which in some cases can be more toxic than the parent compounds. This study aimed to compare the toxicity of IM and one of its impurities (IMP), N-(2-methyl-5-aminophenyl)-4-(3-pyridyl)-2-pyrimidine amine, using progressively complex models.
View Article and Find Full Text PDFObjectives: This mixed-methods study examines the acceptability, feasibility, and preliminary effect of a novel, remotely delivered group intervention (Empower@Home: Connected) targeting depression, social isolation, and loneliness in older adults (≥ 60).
Methods: Acceptability was assessed via participant satisfaction, and feasibility was measured by attrition rates and session attendance. Participants completed pre- and posttest measures of depression, social isolation, and loneliness, with depression also assessed biweekly.
Environ Toxicol
November 2024
J Gerontol Soc Work
January 2025
completed its first season in late 2023. Its companion show, premiered in September of 2024. The reality dating franchise features contestants over the age of 60 and represents an advance in the visibility of older adults in popular media, particularly the dating show genre, while also perpetuating age-related stereotypes.
View Article and Find Full Text PDF